No Bair Hugger plaintiff has won a verdict against 3M, but the Minnesota federal MDL entered 2026 with more than 8,000 pending actions after a full 2019 dismissal was reversed in 2021. The posture makes the litigation an unusually durable test of expert admissibility in forced-air surgical warming cases.
This analysis traces the factual record, MDL proceedings, bellwether outcomes, Rule 702 fight, and settlement pressure shaping the forced-air surgical warming litigation. As in other medical device MDLs, expert admissibility and trial-candidate results drive the outlook.
How the Litigation Grew to 8,411 Pending Cases
The Judicial Panel on Multidistrict Litigation centralized the federal cases on December 11, 2015, and created In re: Bair Hugger Forced Air Warming Devices Products Liability Litigation, MDL No. 2666, No. 0:15-md-02666 (D. Minn. 2015), before Senior District Judge Joan N. Ericksen. The panel's 2026 statistics report lists 8,411 actions pending of 10,712 filed, one of the largest active medical device dockets in the federal system.
Dr. Scott Augustine, an anesthesiologist, invented the device in the mid-1980s; the first unit shipped in 1988. Augustine Medical was reorganized as Arizant Healthcare in 2003, and 3M bought Arizant in Q4 2010 for $810 million cash. The device draws operating-room air through a filter, heats it, and pushes it through a hose into a perforated blanket.
Plaintiffs advance two independent causation theories, both described in the Eighth Circuit's 2021 opinion:
- Airflow disruption: waste heat from the unit creates convection currents that carry ambient bacteria past the operating room's laminar airflow and into the surgical site.
- Internal contamination (the "dirty machine" theory): the device itself harbors bacteria that are blown through the blanket into the operating room and eventually reach the wound.
The named defendant's financial posture has also shifted. Under the Separation and Distribution Agreement effective April 1, 2024, 3M spinoff Solventum indemnifies 3M for uninsured Bair Hugger liabilities, manages the litigation, and pays legal expenses, while 3M remains the named defendant in every underlying suit, per Solventum's Q1 2026 10-Q.
From Full Daubert Dismissal to Amador v. 3M Co. (2021)
Judge Ericksen denied 3M's initial Daubert motions in December 2017, then on July 31, 2019, excluded the plaintiffs' three general-causation medical experts and one engineering expert, granted summary judgment, and directed closure of every remaining member case.
The excluded engineering expert was Dr. Said Elghobashi (computational fluid dynamics); the three medical experts were Drs. William Jarvis, Jonathan Samet, and Michael Stonnington (medicine and epidemiology). The medical experts were excluded because:
- "There is too great an analytical gap between the literature and the experts' general causation opinions;"
- "The experts failed to consider obvious alternative explanations;"
- "The causal inferences made by the experts have not been generally accepted by the scientific community."
For Dr. Elghobashi, the court added that his conclusion rested on an unproven premise and that his CFD simulation "was developed for litigation."
Amador v. 3M Co., 9 F.4th 768 (8th Cir. 2021), undid nearly all of it. Judge Raymond Gruender wrote for a panel that included Judges Jane Kelly and L. Steven Grasz. The panel held the exclusions an abuse of discretion and reversed the medical-expert exclusion in full and the Elghobashi exclusion in part: his testimony is admissible as a factual basis for the medical experts' causation opinions. The panel disagreed that it is per se unreliable for an expert to draw a causation inference from an epidemiological study that itself disclaimed proving causation, and held that "excluding an expert's opinion for being fundamentally unsupported is an exception to the general rule that '[g]aps in an expert witness's . . . knowledge' go to weight, not admissibility."
The Supreme Court denied 3M's certiorari petition (No. 21-1100) on May 16, 2022, with Justice Alito taking no part. That left Amador available to plaintiff firms defending causation experts in device cases.
Gareis v. 3M Co. (2018): The Only Case Tried to Verdict
One federal bellwether has reached a verdict in ten years. The defense won.
In Gareis v. 3M Co., No. 16-cv-4187 (D. Minn. 2018), Louis Gareis underwent hip replacement surgery in November 2010 and developed a joint infection eight months later. The court granted summary judgment on his failure-to-warn claim before trial, so only the strict-liability design-defect claim reached the jury. His trial team, led by attorney Mike Ciresi, presented former company witnesses and a supercomputer simulation mapping the movement of 3 million particles with the device running.
Defense attorney Jerry Blackwell argued no study shows the device contaminates wound sites and emphasized six door openings, staff and equipment movement, and protective measures like gowns, drapes, and taped skin that the plaintiff's models ignored. On May 30, 2018, the jury returned a defense verdict for 3M in under two hours.
Gareis failed to prove his infection would not have occurred but for the Bair Hugger. No compensatory or punitive damages were awarded, and the Eighth Circuit affirmed on August 17, 2021.
The second bellwether, Boncher v. 3M Co., Civil No. 5:24-cv-01403-JMG (E.D. Pa. 2025), ended in a mistrial on May 2, 2025, after three days of deliberation; 3M's Rule 50 motion was denied, and no new trial date has been set. No court filing supports a second bellwether verdict. Gareis stands alone.
The McGovern Disclaimer, the FDA Letter, and Amended Rule 702
The 2011 McGovern observational study remains important because it is historical litigation evidence rather than current scientific support. Plaintiff experts cite its reported association between convective warming and deep-joint infection, while one of its authors testified that the study does not establish a causal basis for that association. That author was a former Augustine employee, and the study's comparator was Augustine's competing HotDog conductive-warming product, though the Augustine side denies funding the work.
The FDA's August 30, 2017 healthcare provider letter carries similar weight in the record: the agency stated it could not identify a consistent association between forced-air thermal regulating systems and surgical site infection and continued to recommend the devices when clinically warranted. An AORN 2025 meta-analysis reported that the pooled data showed no significant increase in surgical site infection risk from forced-air warming use.
The December 2023 Rule 702 amendments add risk. The Advisory Committee Note labels weight-not-admissibility rulings "an incorrect application of Rules 702 and 104(a)," language aimed squarely at decisions like Amador. So far, remanded Bair Hugger courts have kept experts in: Boncher v. 3M Co. (E.D. Pa., February 14, 2025) noted the Eighth Circuit was already applying the preponderance standard before the amendment, and in Robinson v. 3M Co., Case No. 8:24-cv-00828-WFJ-AAS (M.D. Fla. 2025), the court granted in part and denied in part 3M's summary judgment and Rule 702 motions on July 23, 2025, keeping core causation testimony in play, though the case was later dismissed without prejudice on procedural grounds.
Case-Selection Variables for Firms Weighing Inventory
Amador revived the litigation while leaving its economics unresolved. Firms evaluating this docket should treat the following as underwriting inputs, comparable to liens or venue in a valuation.
The Settlement Pressure Picture
No plaintiff verdict exists. One defense verdict and one mistrial leave no damages template, depressing settlement value across inventory. Solventum reported a $31 million accrued Bair Hugger reserve on March 31, 2026, against the full pending docket, and the company states it cannot estimate possible loss beyond that figure. That reserve reflects accounting accrual only, but Solventum remains the recovery source.
A confounding issue carries the same evidentiary character. A 2018 analysis by Jeans and colleagues suggested that screening for methicillin-sensitive Staphylococcus aureus (MSSA) may have skewed the McGovern infection results. Judge Ericksen cited that analysis in 2019, and expert reports that fail to address it invite the same cross-examination that produced the 2019 exclusions.
The Augustine Double Edge
Dr. Augustine is both the litigation's greatest asset and its largest impeachment target. As inventor, his critique carries technical authority. But he sells the competing HotDog warming system, worked with a plaintiff firm in 2013 on a litigation guide for suing 3M, and 3M characterizes his study campaign as a publication factory. Gareis predated the full Augustine record, and no jury has heard it alongside plaintiff causation evidence.
Specific-Causation Screening
Under Boncher v. 3M Co., intake criteria should require culture-confirmed PJI, clear timing tying infection to the arthroplasty where the device was used, a differential ruling out skin flora, OR personnel, instruments, and bloodstream sources, and no obvious comorbidity-based infection route. Cases missing any element face dismissal risk independent of general causation.
Benchmarks That Will Decide the Docket's Direction
The MDL is in a trial-and-screening phase, with periodic status conferences continuing before the magistrate judge. A plaintiff verdict would create the clearest pressure point. A global settlement or qualified settlement fund would also reshape underwriting. As of the August 2025 status report, summary judgment and Rule 702 motions in several trial-candidate cases remained under advisement. An amended-rule exclusion would face a friendlier appellate posture than the 2019 orders Amador reversed, so a second dismissal would be harder to undo.
Plaintiff Bellwether Verdict
Two District of South Carolina trial candidates, Fratino and Finley, carry conditional trial dates of March 2, 2026, and May 11, 2026, each set to follow resolution of the pending Rule 56 motion. A plaintiff win would establish a damages template and pressure a reserve that does not price docket-wide liability.
Global Settlement or Qualified Settlement Fund
None has been announced. The special master concluded in 2023 that additional trials are necessary to help move the docket toward resolution, and settlement discussions have continued without a global resolution. For comparison, the breathing-device manufacturer settled its claims only after extensive bellwether proceedings established a claims-administration framework.
What the Docket Teaches About Daubert Risk
For plaintiff counsel, Amador's preponderance language survives the 2023 amendment. Reports will hold post-amendment only if they walk each causal link and address MSSA confounding head-on, and they also need distance from Augustine-affiliated research.
For defense counsel, the amended Committee Note and the 2017 FDA letter form a repeatable exclusion playbook outside the Eighth Circuit, with the McGovern disclaimer adding case-specific support. Firms on either side should track the pending Rule 702 rulings before committing trial resources, and plaintiff firms should price Solventum's financial capacity, not 3M's, into any settlement model. For a parallel study of expert admissibility deciding a mass tort's trajectory, see the J&J ovarian-cancer litigation analysis.
